MedPage Today July 30, 2024
— Slower cognitive decline, less brain volume loss in early liraglutide study
PHILADELPHIA — A GLP-1 receptor agonist may have the ability to protect cognition in people with mild Alzheimer’s dementia, data from the phase IIb ELAD trial suggested.
Liraglutide (Saxenda, Victoza) showed benefit on one of three secondary outcomes that measured cognition, reported Paul Edison, MD, PhD, of Imperial College London, at the Alzheimer’s Association International Conference.
On the ADAS-Exec score — a cognitive outcome that combined the Alzheimer’s Disease Assessment Scale-Cognitive subscale and the executive domain portions of the Neuropsychological Test Battery — participants who completed 52 weeks of liraglutide treatment had a statistically significant slowing of cognitive decline (P<0.01), Edison said.
The trial was not powered to...
Today's Sponsors
Today's Sponsor